Update on FDA Medical Device Quality Initiatives

MedCon 2014


Steve Silverman, Director
CDRH Office of Compliance
May 7, 2014

Agenda


- Why a quality strategy?
- How does quality differ from compliance?
- FDA Quality Initiatives:
 - The Case for Quality (CfQ)
 - The Voluntary Compliance Improvement Pilot (VCIP)
- The Office of Compliance Reorganization

Why a Quality Strategy?

2005-2013 FDA Form 483 Observations



2005-2013 Inspections with OAI Outcomes



- We are consistently seeing a high volume of the same issues year after year
- We must ask
 whether we are
 using the right
 methods to improve
 device quality


Why a Quality Strategy?




Domestic; Annual

Percent of firms inspected

Foreign; Annual






Inspected


Not inspected

122 Warning Letters were issued in the 2012 calendar year – 3.8% of total investigations resulted in a Warning Letter


Quality Versus Compliance: Current State



Quality Versus Compliance: Future State



FDA Quality Initiatives



The Case for Quality

- Support and ownership of quality go beyond quality/compliance units
- A culture of quality yields benefits.
- Recent trends highlight the importance of quality.
- "Understanding Barriers to Medical Device Quality" http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM277323.pdf
- October 31, 2011 webcast: http://fda.yorkcast.com/webcast/Viewer/?peid=7134123bd5c94d909fdae41fce3469411d
- http://fda.yorkcast.com/webcast/Viewer/?peid=7134123bd5c94d909fdae41fce3469411d

The Case for Quality Implementation Plan

Initiative 1: Focus on Quality

Initiative 2: Enhanced Transparency

Initiative 3: Stakeholder Engagement

What have we heard?

Stakeholders

- 1. Safe communications
- 2. Collaboration
- 3. Inspection engagement
- 4. Critical to quality
- 5. Clear expectations
- 6. Incentives

Internally

- 1. Communications
- 2. Collaboration
- 3. Inspection engagement
- 4. Critical to quality
- 5. Clear expectations
- 6. Incentives


2014 Case for Quality Activities

Sub-Initiative Activities Develop, implement, and assess a pilot that changes 1. engagement during an inspection **Focus on Quality** 2. Assess internal/external incentives and measures Benchmark with other quality performance models Provide relevant device quality data 1. Gather and assess stakeholder data needs **Data Transparency** Develop a framework for delivering releasable information 1. Engage industry and other stakeholders in national venues Stakeholder **Engage industry and FDA districts in local venues Engagement** Partner with industry and other stakeholders to develop 3. collaborative forums and trustful engagements

Case for Quality: Battery Pilot

- Implantable Battery-Containing Devices
- Up to 5 Manufacturers
- Inspections focused on factors that affect device quality
- Prioritized Form FDA-483s
- Does the pilot improve quality and resource allocation?

Successful pilots can be expanded.




The Voluntary Compliance Improvement Pilot

- CDRH Strategy 4.2. Establish a Voluntary Compliance Improvement Pilot Program
 - Goal 4.2.1. By September 30, 2013, CDRH will take steps to move certain manufacturers at risk of compliance action . . . to a state of improved performance by allowing these manufacturers to enter into a remediation agreement with the agency
 - By September 30, 2013, launch the Voluntary Compliance Improvement Pilot Program.

Voluntary Compliance Improvement Pilot

- Up to 5 manufacturers
- Alternative to surveillance inspections
- Expert consultants certify that participants have defined problems, analyzed root causes, and taken effective corrective action.
- Manufacturers self-identify and correct deficiencies; FDA redirects resources to firms unable to take these steps.

The Office of Compliance is reorganizing:



The Office of Compliance is reorganizing:

